Market capitalization | $2.86b |
Enterprise Value | $2.24b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.62 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-213.02m |
Free Cash Flow (TTM) Free Cash Flow | $-137.65m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
2 Analysts have issued a Morphic Holding Inc forecast:
2 Analysts have issued a Morphic Holding Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.12 -1.12 |
115%
115%
|
|
EBITDA | -212 -212 |
50%
50%
|
EBIT (Operating Income) EBIT | -213 -213 |
49%
49%
|
Net Profit | -180 -180 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.
Head office | United States |
CEO | Praveen Tipirneni |
Employees | 121 |
Founded | 2014 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.